These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 28923315)

  • 21. Quantification of HBsAg and HBV-DNA during therapy with peginterferon alpha-2b plus lamivudine and peginterferon alpha-2b alone in a German chronic hepatitis B cohort.
    Wiegand J; Brosteanu O; Kullig U; Wiese M; Berr F; Maier M; Tillmann HL; Schiefke I
    Z Gastroenterol; 2011 Nov; 49(11):1463-9. PubMed ID: 22069045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reverse transcriptase droplet digital PCR vs reverse transcriptase quantitative real-time PCR for serum HBV RNA quantification.
    Limothai U; Chuaypen N; Poovorawan K; Chotiyaputta W; Tanwandee T; Poovorawan Y; Tangkijvanich P
    J Med Virol; 2020 Dec; 92(12):3365-3372. PubMed ID: 32219874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance.
    Hsu CW; Yeh CT; Chang ML; Liaw YF
    Gastroenterology; 2007 Feb; 132(2):543-50. PubMed ID: 17258721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential roles of serum hepatitis B virus DNA and hepatitis B surface antigen level in predicting virological breakthrough in patients receiving lamivudine therapy.
    Su CW; Wu CY; Hung HH; Wu CH; Sheen IJ; Wu JC
    J Gastroenterol Hepatol; 2013 Dec; 28(12):1849-58. PubMed ID: 23730852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complete hepatitis B virus prophylaxis withdrawal in hepatitis B surface antigen-positive liver transplant recipients after longterm minimal immunosuppression.
    Lenci I; Baiocchi L; Tariciotti L; Di Paolo D; Milana M; Santopaolo F; Manzia TM; Toti L; Svicher V; Tisone G; Perno CF; Angelico M
    Liver Transpl; 2016 Sep; 22(9):1205-13. PubMed ID: 27272189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors associated with serum hepatitis B surface antigen levels and its on-treatment changes in patients under lamivudine therapy.
    Chen J; Wang Z; Zhou B; Wang Y; Hou J
    Antivir Ther; 2012; 17(1):71-9. PubMed ID: 22267471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load.
    Pan CQ; Duan Z; Dai E; Zhang S; Han G; Wang Y; Zhang H; Zou H; Zhu B; Zhao W; Jiang H;
    N Engl J Med; 2016 Jun; 374(24):2324-34. PubMed ID: 27305192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative detection of hepatitis B virus DNA in serum by a new rapid real-time fluorescence PCR assay.
    Jardi R; Rodriguez F; Buti M; Costa X; Cotrina M; Valdes A; Galimany R; Esteban R; Guardia J
    J Viral Hepat; 2001 Nov; 8(6):465-71. PubMed ID: 11703579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study.
    Moucari R; Korevaar A; Lada O; Martinot-Peignoux M; Boyer N; Mackiewicz V; Dauvergne A; Cardoso AC; Asselah T; Nicolas-Chanoine MH; Vidaud M; Valla D; Bedossa P; Marcellin P
    J Hepatol; 2009 Jun; 50(6):1084-92. PubMed ID: 19376603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
    Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapid quantification of hepatitis B virus DNA by real-time PCR using fluorescent hybridization probes.
    Ho SKN; Yam WC; Leung ETK; Wong LP; Leung JKH; Lai KN; Chan TM
    J Med Microbiol; 2003 May; 52(Pt 5):397-402. PubMed ID: 12721315
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of tenofovir disoproxil fumarate to prevent vertical transmission in mothers with lamivudine-resistant HBV.
    Wang J; Liu J; Qi C; Yan T; Cao F; Jin L; He Y; Yang Y; Zhang S; Chen T; Zhao Y
    Antivir Ther; 2015; 20(7):681-7. PubMed ID: 26215771
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Persistence of hepatitis B virus in children after interferon-alpha therapy despite the seroconversion in HBsAg/anti-HBs system].
    Gregorek H; Dzierzanowska-Fangrat K; Woynarowski M; Jóźwiak P; Witkowska-Vogtt E; Wojda U; Syczewska M; Socha J; Madalińiski K
    Przegl Epidemiol; 2005; 59(3):641-9. PubMed ID: 16433306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
    Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
    Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance.
    Lee S; Ahn SH; Jung KS; Kim DY; Kim BK; Kim SU; Baatarkhuu O; Ku HJ; Han K; Park JY
    J Viral Hepat; 2017 Feb; 24(2):141-147. PubMed ID: 27766731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Droplet-digital polymerase chain reaction for detection of clinical hepatitis B virus DNA samples.
    Yang D; Hu T; Wu X; Li K; Zhong Q; Liu W
    J Med Virol; 2018 Dec; 90(12):1868-1874. PubMed ID: 30085351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response.
    Jain MK; Comanor L; White C; Kipnis P; Elkin C; Leung K; Ocampo A; Attar N; Keiser P; Lee WM
    J Viral Hepat; 2007 Mar; 14(3):176-82. PubMed ID: 17305883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from Côte d'Ivoire.
    Boyd A; Moh R; Gabillard D; le Carrou J; Danel C; Anglaret X; Eholié SP; Maylin S; Delaugerre C; Zoulim F; Girard PM; Lacombe K;
    Antivir Ther; 2015; 20(6):643-54. PubMed ID: 25852125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of HBV DNA decay kinetics in patients containing both rtM204V/I mutant and wild-type HBV subpopulations during tenofovir DF (TDF) monotherapy or combination therapy with emtricitabine (FTC)/TDF.
    Liu Y; Fung S; Gane EJ; Dinh P; Flaherty JF; Svarovskaia ES; Miller MD; Kitrinos KM
    J Med Virol; 2014 Sep; 86(9):1473-81. PubMed ID: 24861361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
    Maklad S; Doss W; El Din SS; Hassan K; Zeid AA
    Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.